Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 273Carcinoma, Non-Small-Cell Lung 224Prostatic Neoplasms 181Neoplasms 174Lung Neoplasms 137Multiple Myeloma 136Neoplasm Metastasis 101Colorectal Neoplasms 100Melanoma 87Ovarian Neoplasms 80Leukemia, Myeloid, Acute 74Pancreatic Neoplasms 73Lymphoma 69Carcinoma, Renal Cell 65Leukemia, Lymphocytic, Chronic, B-Cell 64Brain Neoplasms 63Lymphoma, Non-Hodgkin 62Squamous Cell Carcinoma of Head and Neck 61Recurrence 56Urinary Bladder Neoplasms 55Hematologic Neoplasms 55Carcinoma, Hepatocellular 54Head and Neck Neoplasms 53Triple Negative Breast Neoplasms 51Lymphoma, Follicular 48Glioblastoma 48Endometrial Neoplasms 47Uterine Cervical Neoplasms 45Precursor Cell Lymphoblastic Leukemia-Lymphoma 45Sarcoma 44

Interventions

cemiplimab 1Pemetrexed 1Paclitaxel 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Resectable Non-small Cell Lung Cancer × 90 days × Clear all
NCT06161441 2026-05-28

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

Regeneron Pharmaceuticals

Phase 2 Active not recruiting
195 enrolled
Thoracic

Resectable Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡